William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on TransMedics Group (TMDX – Research Report). The associated price target was raised to $129.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
William Plovanic has given his Buy rating due to a combination of factors including strong growth trends in the transplant market, particularly in the heart and liver segments. The April data from UNOS indicates a robust increase in heart and DCD liver transplants, with heart transplants showing a 6% month-over-month growth and DCD liver transplants experiencing a 9% increase. These trends are significant as they highlight the growing adoption of TransMedics Group’s OCS System, especially in the DCD liver market, which has historically driven growth.
Additionally, the year-over-year growth figures are impressive, with DCD liver transplants up by 82% and DCD heart transplants increasing by 68%. These positive trends in the transplant market suggest a favorable environment for TransMedics Group’s products, supporting Plovanic’s optimistic outlook on the company’s stock. Despite a slight decline in lung transplants, the overall market dynamics and the company’s position in the heart and liver segments underpin the Buy rating.
Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, Tandem Diabetes Care, and Atricure. According to TipRanks, Plovanic has an average return of 3.8% and a 45.74% success rate on recommended stocks.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $130.00 price target.